Roche subsidiary Genentech on Wednesday released data from the Phase III OCARINA II study, showing that its investigational subcutaneous formulation for Ocrevus (ocrelizumab) strongly reduced relapses and brain lesions in patients with relapsing or primary progressive multiple sclerosis.
Featured Posts
Like its branded reference product, Selarsdi is a subcutaneous injection that can be used to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in pediatric and adult patients. Unlike Stelara, however, Selarsdi is not approved for Crohn’s disease and ulcerative colitis.
The German cartel office has approved a deal by Denmark’s Novo Nordisk (NOVOb.CO) to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.
Cerevel Therapeutics reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.
With continued success, Elahere will not only infiltrate the endometrial cancer market but also pave the way for future treatment strategies with an ADC and immunotherapy combination, says GlobalData.
According to the agency’s website, most doses of Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand.
Generic drugs present a notable absence of consensus among physicians within the realm of healthcare regarding patients’ choice between branded and generic alternatives. This lack of a clear stance among healthcare providers prompts an in-depth investigation into the myriad factors shaping their perspectives, including efficacy, patient preferences, and cost considerations.
Bayer continued its leadership shuffle not only at its world headquarters in Germany but at two U.S.–based subsidiaries. Yet most of the executive movement of late has been at smaller companies.
At this week’s American Academy of Neurology annual meeting, Amylyx provided additional data from its Phase III amyotrophic lateral sclerosis study showing the full extent of Relyvrio’s failure.
The trial results add to a growing body of clinical evidence that suggests GLP-1 drugs, which include popular treatments such as Lilly’s Mounjaro and Novo Nordisk’s Wegovy, have medical benefits beyond diabetes and weight loss.